sábado, 7 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 16, 2026

Taiwan Semi raises 2026 outlook after Q1 profit surges amid AI demand

View original at seekingalpha.com
“"From what I remember, the market was initially fearing that TSMC was nearing the peak in margins, but in Q1, we saw an expansion from ~58% in GP margin to over 66%, which is insanely solid for such a large entity."”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI-related demand continues to be extremely robust

    60% confidence
  • Historically, TSMC does not add additional capacity to a node once it has reached its target capacity, but is stepping up CapEx investment to increase N3 capacity to meet strong demand in AI application

    60% confidence
  • Q1 earnings solid with gross and operating margins above guidance; Q2 guidance above expectations with continued margin expansion; TSMC confident in market share; lack of meaningful revenue and capex upside may be mild disappointment but estimates likely to move up over next 2-3 quarters

    60% confidence
  • At TSMC, a higher level of capital expenditures is always correlated with higher growth opportunities in the following years

    60% confidence
  • TSMC remains committed to a sustainable and steadily increasing cash dividend per share on both an annual and quarterly basis

    60% confidence
  • TSMC saw gross margin expansion from ~58% to over 66% in Q1, showing major pricing power and superior execution, with business mix shifting toward higher-value products; rates stock a buy after the print

    60% confidence
  • Given the recent situation in the Middle East, prices for certain chemicals and gases are likely to increase, which may impact profitability but it is too early to quantify

    60% confidence
  • TSMC forecasts gross margin dilution from overseas fab ramp-up to be 2-3% in early stages and widen to 3-4% in latter stages

    60% confidence
  • TSMC does not expect any near-term impact on operations for material supply and works closely with Taipower and Taiwan government to ensure stable and sufficient energy supply

    60% confidence
  • Raised 2026 sales guidance and capex guidance is a positive surprise; stronger conviction reflects stronger-for-longer Cloud AI demand and requirement to speed-up capacity expansion

    60% confidence
  • With another strong quarter, stronger Q2 forecast, and competitive risk seemingly years away, Wedbush sees no reason to shift constructive view on TSMC

    60% confidence
  • Initial ramp-up of 2nm technology will start to dilute gross margin in H2 2026 with expected 2-3% dilution for full year 2026

    60% confidence
  • Moving into second quarter 2026, business expected to be supported by continued strong demand for leading-edge process technologies

    60% confidence
  • Our business in the first quarter was supported by strong demand for our leading-edge process technologies

    60% confidence
  • Best highlight is 66.2% GM reported for Q1 2026 and 66.5% GM guided for Q2 2026; AI demand outlook remains robust; TSMC trying to balance customer demand and avoiding CapEx overrun; history shows betting on TSMC margin compression has negative risk/reward

    60% confidence

Data points we hold from this source

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,996
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,996 hechos verificados con la fuente5,552 documentos fuente archivados
Consulta estos datos → isubstrate.com
Taiwan Semi raises 2026 outlook after Q1 profit surges amid AI demand — Source | Via News | es.VIA.NEWS